(HealthDay): For adults recently diagnosed with type 2 diabetes mellitus (T2DM), delays in first-line therapy are longer for older patients, those who are black or of other ethnicities, and those with multimorbidity, according to a study published online 29 inches Diabetes, obesity and metabolism.
Dr. primary care between 2000 and 2018.
The researchers found this elderly patients, those who are black or of other ethnicities, and those with multimorbidity had the longest delays in prescribing first-line therapy. Compared to those in the most disadvantaged areas, patients in the most disadvantaged areas received previous first-line treatment. Most patients were treated with metformin, sulfonylurea, dipeptidyl peptidase IV inhibitors, and insulin as first-, second-, third-, and fourth-line prescriptions, respectively (82.4, 50.4, 27.7, and 28.0 percent, respectively). The mean time to prescription was 0.5, 4.1, 4.6, and 4.7 years for first-, second-, third-,,, and fourth-line glucose reduction therapy, respectively. Twenty-five percent of patients developed cardiovascular and non-cardiovascular diseasecardiovascular disease complications within an average of 12 to 14 years after diagnosis of T2DM and received intensification five to six years later.
“Most patients with T2DM continue to maintain poor glycemic control and experience delays in early intensification of treatment despite a greater number of therapies available,” the authors write. “We recommend future health research and guidelines to focus on overcoming therapeutic inertia.”
An author revealed his work with Novo Nordisk.
Summary / Full text (subscription or payment may be required)
Copyright © 2021 HealthDay. All rights reserved.
Citation: Glucose Reducing Therapy for Newly Diagnosed T2DM Patients (2021, July 6), Retrieved July 6, 2021 at https://medicalxpress.com/news/2021-07-glucose-lowering, Delayed -therapy-newly-t2dm-patients.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.
